NAT10 and liver cancer: In conclusion, these results collectively demonstrate that NAT10‐2023 exhibits strong therapeutic potential for liver cancer, effectively inhibiting tumor growth, reducing metastasis, suppressing hepatocarcinogenesis, preventing fibrosis, and preserving liver function across various preclinical models.